---
title: "FDA Cybersecurity Testing Requirements: What Medical Device Makers Must Actually Prove"
meta_title: "FDA Cybersecurity Testing Requirements Explained (2026 Guide)"
meta_description: "A clear, journalistic breakdown of FDA cybersecurity testing requirements for medical devices — from risk-based scope and SBOMs to penetration testing, documentation, and lifecycle duties under Section 524B."
slug: "fda-cybersecurity-testing-requirements"
primary_keyword: "FDA cybersecurity testing requirements"
secondary_keywords:
  - "medical device cybersecurity"
  - "Section 524B FD&C Act"
  - "premarket cybersecurity submission"
  - "SBOM medical devices"
  - "penetration testing medical devices"
  - "healthcare cybersecurity careers"
category: "Cybersecurity"
audience: "WomenTech Network — technologists, security engineers, and leaders"
date: "2026-10-22"
reading_time: "9 min"
---

# FDA Cybersecurity Testing Requirements: What Medical Device Makers Must Actually Prove

**TL;DR —** The FDA does not hand manufacturers a fixed checklist of security tests. Instead, under Section 524B of the Federal Food, Drug, and Cosmetic (FD&C) Act and the agency's 2023 premarket guidance, it expects companies to tie every test back to the device's own risk profile and to prove — with evidence — that security controls work and keep working. In practice that means threat modeling, a software bill of materials (SBOM), penetration and fuzz testing, authentication and interface checks, secure-communications validation, resilience testing, and a documented plan to patch vulnerabilities after launch. Testing is a lifecycle obligation, not a last-minute formality.

---

Medical devices have quietly become some of the most connected objects in a hospital. An infusion pump talks to a drug library over Wi-Fi. A pacemaker streams telemetry to a clinician's dashboard. A glucose monitor pairs with a phone app that syncs to the cloud. Each connection delivers real benefits — faster data, remote monitoring, better clinical decisions. Each also widens the attack surface of equipment that patients depend on.

That shift is why cybersecurity has moved from an afterthought in medical device engineering to a gating requirement for market access. Since March 2023, the U.S. Food and Drug Administration has been empowered to **refuse to accept** premarket submissions for many connected devices that lack adequate cybersecurity information. Understanding what the agency actually tests for — and what it expects manufacturers to prove — has become essential knowledge, not only for regulatory teams but for the security engineers, product leaders, and clinical-tech professionals who build and defend these systems.

This is a field where demand for skilled people far outpaces supply, and it is one of the more accessible on-ramps for technologists — including the many women building careers in security and healthcare tech — who want work that is technically deep and demonstrably consequential.

For a comprehensive, structured reference that organizes these obligations into a usable taxonomy, this detailed guide to the [FDA cybersecurity testing requirements](https://bluegoatcyber.com/guides/fda-cybersecurity-testing-requirements-taxonomy) is a strong companion to the overview below.

## What are the FDA's cybersecurity testing requirements for medical devices?

The FDA's cybersecurity testing requirements are a **risk-based set of expectations**, not a single mandated test suite. They flow primarily from two sources: **Section 524B of the FD&C Act** (added by the Consolidated Appropriations Act of 2023), which makes cybersecurity information a condition of premarket submission for "cyber devices," and the FDA's 2023 final guidance, *Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions.*

Together they require manufacturers of connected devices to:

- Submit a plan to **monitor, identify, and address** post-market vulnerabilities and exploits, including coordinated disclosure.
- Design, develop, and maintain processes that provide **reasonable assurance** the device and related systems are secure.
- Make available **security updates and patches** — both on a regular cadence and out-of-cycle for critical issues.
- Provide a **software bill of materials (SBOM)** covering commercial, open-source, and off-the-shelf software components.
- Demonstrate, through testing, that identified risks are controlled and the controls actually work.

The word doing the heavy lifting is *demonstrate*. The agency wants objective evidence linking identified risks to specific controls to concrete test results.

## Why testing starts with the device's risk profile

No two devices face the same threats. A networked imaging system that receives remote commands and stores protected health information requires a far deeper assessment than a device with minimal connectivity. That is why the FDA anchors testing to the **device's threat model and security architecture** rather than a universal template.

The logic is straightforward: identify reasonably foreseeable threats, map how an attacker or failure could affect the device, evaluate whether the resulting risk to patient safety is adequately controlled — then **test the controls that address those risks.** If a manufacturer flags unauthorized access as a hazard, testing must show authentication and access controls hold. If patching is the strategy for emerging vulnerabilities, the update mechanism itself must be assessed. Security testing that is disconnected from the threat model produces findings, not assurance.

## The scope goes well beyond vulnerability scanning

A common misconception is that cybersecurity testing means running a scanner and fixing what it flags. Automated scanning is useful for catching known weaknesses in operating systems, libraries, and network services — but it is a starting point, not the destination.

Depending on the device and its risk, a credible testing program may include:

- **Penetration testing** — examining whether vulnerabilities can actually be chained and exploited to real safety or security consequences.
- **Fuzz testing** — bombarding interfaces with malformed input to surface crashes and unhandled conditions.
- **Authentication and access-control testing** — verifying that users, systems, and services are properly identified and limited to appropriate privileges.
- **Interface and attack-surface testing** — probing debug ports, service interfaces, APIs, wireless links, and maintenance tools that rarely appear in the main UI.
- **Secure-communications testing** — validating encryption, certificate handling, key management, and protocol behavior.
- **Software security and SBOM analysis** — evaluating third-party and open-source components against known vulnerabilities.

Penetration testing earns particular attention because it tests *exploitability*, not just the presence of a flaw. A theoretical weakness may be harmless in isolation; a chain of minor ones can hand an attacker control. Testing that follows realistic attack paths yields far more useful evidence than isolated findings viewed without context.

## Why the software bill of materials (SBOM) matters so much

Modern devices are assembled, not written from scratch. They lean on open-source libraries, commercial middleware, and legacy operating systems built outside the manufacturer's walls. Those dependencies accelerate innovation — and quietly import vulnerabilities the manufacturer must still own.

You cannot assess what you cannot see. The **SBOM** gives the FDA, and the manufacturer, a reliable inventory of what software actually lives inside a device, so newly disclosed vulnerabilities can be matched against deployed components. Crucially, a vulnerability's mere presence does not condemn a device: manufacturers are expected to judge whether it is *exploitable in this device's environment*, what the consequences would be, and whether existing controls already reduce the risk to an acceptable level.

## Authentication, access controls, and hidden interfaces

Every pathway a device uses to talk to clinicians, patients, hospital systems, phones, or the cloud is a potential way in. Testing must therefore scrutinize how access to functions and data is controlled.

Authentication testing checks that identities are verified before access is granted. Access-control testing confirms that authenticated users stay inside their lane — a service technician, an administrator, a clinician, and a patient should not share the same privileges. And a thorough assessment deliberately hunts for the **less-visible interfaces**: debug ports left open, undocumented service modes, maintenance tools, and remote-administration functions that attackers love precisely because defenders forget them.

## Secure communications and data integrity

When a device transmits or receives information, the FDA expects protection appropriate to the data and the stakes. Testing may evaluate encryption implementation, certificate and key management, protocol choices, and how the device reacts to manipulated or invalid data.

Confidentiality is only half the story. In healthcare, **altered data can be as dangerous as stolen data.** A tampered measurement, a modified command, or a corrupted software package can drive an incorrect clinical decision or unsafe device behavior. Testing should therefore probe whether an attacker could modify commands, readings, configuration, or firmware in transit or at rest — because the trustworthiness of information is a safety property, not just a privacy one.

## Resilience: how the device behaves when controls fail

Controls fail and vulnerabilities surface after launch. A mature program assumes this and tests for it. **Resilience testing** asks whether the device preserves safe, essential functionality during abnormal conditions, communication loss, malicious input, or active attack.

The right response is device-specific. Sometimes continued operation is non-negotiable; sometimes failing into a documented **safe state** is the correct behavior. Either way, the manufacturer should be able to show the device was designed and tested on the expectation that security failures and unexpected conditions *will* occur.

## Documentation is the evidence

In a regulatory context, an untested-looking test is no test at all. Documentation is what connects cybersecurity activity to the broader design-control and risk-management process. A strong record lets a reviewer trace each significant risk to a control and to the validation that exercised it: test plans, methods, results, findings, remediation decisions, and residual-risk assessments.

It also has to handle **unresolved findings honestly.** Not every issue can be eliminated before launch, and some carry little practical weight. What matters is a reasoned, consistent basis for each decision — evidence that findings were evaluated systematically rather than ignored.

## Cybersecurity is a lifecycle obligation, not a launch gate

The clearance or authorization date is the beginning, not the end. Threats evolve, new CVEs land, and the software environment around a device shifts. Section 524B's emphasis on **post-market monitoring, coordinated disclosure, and the ability to ship timely patches** reflects a now-standard view across regulators, hospitals, and security teams: a device's security posture cannot be frozen at the moment it ships.

Manufacturers need live processes to monitor vulnerabilities, assess their relevance to fielded products, and act when correction is warranted — and to communicate clearly with the healthcare organizations running the devices.

## The talent dimension: a growing field for security professionals

The practical effect of these requirements is a surge in demand for people who sit at the intersection of security engineering, embedded systems, and regulatory knowledge. Device manufacturers, hospitals, and specialized consultancies are hiring product security engineers, penetration testers, SBOM and vulnerability analysts, and regulatory-affairs specialists faster than the pipeline can fill the roles.

For technologists weighing where to specialize — including the growing community of women in cybersecurity and health tech — medical device security offers an unusually clear value proposition: the work is technically rigorous, the regulatory framework gives it durability, and the outcome is measured in patient safety rather than abstract compliance. It is a field where getting the testing right genuinely matters.

## Key takeaways

- **It's risk-based, not checklist-based.** Scope follows the device's threat model, connectivity, and potential patient-safety impact.
- **Scanning is the floor, not the ceiling.** Penetration, fuzz, authentication, interface, and resilience testing all play a role.
- **An SBOM is foundational.** You can only manage the vulnerabilities in components you can actually see.
- **Integrity matters as much as confidentiality.** Altered clinical data is a safety hazard.
- **Documentation is the proof.** Traceability from risk → control → test result is what reviewers look for.
- **Security is a lifecycle duty.** Post-market monitoring and timely patching are now legal expectations under Section 524B.

## Frequently asked questions

**What is Section 524B of the FD&C Act?**
Section 524B, added by the Consolidated Appropriations Act of 2023, requires manufacturers of "cyber devices" to include cybersecurity information in premarket submissions — including a vulnerability-management plan, assurance of secure design, a patch and update process, and a software bill of materials. The FDA can refuse to accept submissions that don't meet it.

**Does the FDA require penetration testing for medical devices?**
The FDA does not mandate a single named test, but its 2023 guidance expects testing appropriate to the device's risk, and penetration testing is widely used because it demonstrates whether vulnerabilities are actually exploitable. For higher-risk, connected devices, reviewers generally expect to see it.

**What is an SBOM and why does the FDA want one?**
A software bill of materials is an inventory of all software components in a device, including open-source and commercial off-the-shelf code. It lets both the manufacturer and the FDA match newly disclosed vulnerabilities to affected products so they can be assessed and patched.

**Is cybersecurity testing a one-time, premarket activity?**
No. It is a lifecycle responsibility. Manufacturers must monitor for new vulnerabilities, assess their relevance to fielded devices, and provide security updates and patches — on a regular schedule and out-of-cycle for critical issues.

**Who performs medical device cybersecurity testing?**
A mix of in-house product security teams and independent specialists. Common roles include product security engineers, penetration testers, vulnerability and SBOM analysts, and regulatory-affairs professionals — a fast-growing set of career paths in healthcare cybersecurity.

---

### Sources and further reading

- FDA, *Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions* (final guidance, September 2023).
- Section 524B, Federal Food, Drug, and Cosmetic Act (added by the Consolidated Appropriations Act, 2023).
- Blue Goat Cyber, *A detailed breakdown of the [FDA cybersecurity testing requirements](https://bluegoatcyber.com/guides/fda-cybersecurity-testing-requirements-taxonomy).*

---

> **Editor's note / schema suggestion:** When publishing, mark up the "Frequently asked questions" section with `FAQPage` structured data and the article body with `Article` (or `NewsArticle`) schema to maximize eligibility for rich results and answer-engine extraction. Set the canonical primary keyword to *FDA cybersecurity testing requirements* and keep the single external do-follow link on the exact-match anchor above.
